New data from an independent prospective study presented last week at the 19th European Congress of Psychiatry (EPA 2011) shows treatment with Risperdal® Consta® (risperidone long-acting injection (RLAI)) is associated with a lower risk of hospitalisation in patients with schizophrenia compared to treatment with other antipsychotics over a 12-month period…

Originally posted here:
Risperdal(R) Consta(R) Associated With Lower Risk Of Hospitalisation Compared To Treatment With Other Antipsychotics In Patients With Schizophrenia